Anti-arrhythmic drugs for patients with paroxysmal or persistent atrial fibrillation or flutter, current to sinus rhythm or need cardioerter recent atrial fibrillation or flutter coexist in patients with cardiovascular disease risk factors
*The following content is generated by AI and is for reference only.
Dronedarone Hydrochloride is a non-glycosidic antiarrhythmic agent belonging to the class of benzofuran derivatives, chemically related to amiodarone but engineered to minimize severe extracardiac toxicity. Its molecular formula is C35H42ClNO6S·HCl, and it carries the CAS Registry Number 178069-08-2 for the hydrochloride salt form. This medication functions primarily as a multi-channel blocker, inhibiting potassium, sodium, and calcium currents within cardiac myocytes while also antagonizing adrenergic receptors. By modulating these ion channels, Dronedarone effectively prolongs the action potential duration and refractory period, thereby stabilizing heart rhythm in patients suffering from atrial fibrillation or atrial flutter.
Clinically, Dronedarone Hydrochloride is indicated for the maintenance of normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation who have risk factors for cardiovascular death. Unlike its predecessor amiodarone, which is associated with significant thyroid, pulmonary, and hepatic toxicities due to its high iodine content and long half-life, Dronedarone lacks iodine and exhibits a more favorable safety profile regarding organ damage. It is metabolized extensively by the cytochrome P450 3A4 enzyme system, necessitating careful monitoring of potential drug-drug interactions, particularly with strong CYP3A4 inhibitors or other QT-prolonging agents. The drug is typically administered orally in tablet form, usually at a dose of 400 mg twice daily. Despite its improved tolerability, contraindications include permanent atrial fibrillation, decompensated heart failure, and severe liver impairment, where the risk of adverse outcomes outweighs therapeutic benefits. Ongoing research continues to explore its efficacy in broader arrhythmia management strategies, solidifying its role as a safer alternative for long-term rhythm control in selected patient populations requiring intervention against irregular heartbeats without the burden of severe systemic side effects.